Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 16

1.

Importance of TP53 codon 72 and intron 3 duplication 16bp polymorphisms in prediction of susceptibility on breast cancer.

Costa S, Pinto D, Pereira D, Rodrigues H, Cameselle-Teijeiro J, Medeiros R, Schmitt F.

BMC Cancer. 2008 Jan 29;8:32. doi: 10.1186/1471-2407-8-32.

2.

Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer.

Liu X, Holstege H, van der Gulden H, Treur-Mulder M, Zevenhoven J, Velds A, Kerkhoven RM, van Vliet MH, Wessels LF, Peterse JL, Berns A, Jonkers J.

Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):12111-6.

3.
4.

Common variants in the ATM, BRCA1, BRCA2, CHEK2 and TP53 cancer susceptibility genes are unlikely to increase breast cancer risk.

Baynes C, Healey CS, Pooley KA, Scollen S, Luben RN, Thompson DJ, Pharoah PD, Easton DF, Ponder BA, Dunning AM; SEARCH breast cancer study..

Breast Cancer Res. 2007;9(2):R27.

5.

Evidence for an association of TP53 codon 72 polymorphism with breast cancer risk.

Damin AP, Frazzon AP, Damin DC, Roehe A, Hermes V, Zettler C, Alexandre CO.

Cancer Detect Prev. 2006;30(6):523-9.

PMID:
17113725
6.

A haplotype containing the p53 polymorphisms Ins16bp and Arg72Pro modifies cancer risk in BRCA2 mutation carriers.

Osorio A, Martínez-Delgado B, Pollán M, Cuadros M, Urioste M, Torrenteras C, Melchor L, Díez O, De La Hoya M, Velasco E, González-Sarmiento R, Caldés T, Alonso C, Benítez J.

Hum Mutat. 2006 Mar;27(3):242-8.

PMID:
16419081
7.

A weighted cohort approach for analysing factors modifying disease risks in carriers of high-risk susceptibility genes.

Antoniou AC, Goldgar DE, Andrieu N, Chang-Claude J, Brohet R, Rookus MA, Easton DF.

Genet Epidemiol. 2005 Jul;29(1):1-11.

PMID:
15880399
8.

BRCA1 shifts p53-mediated cellular outcomes towards irreversible growth arrest.

Ongusaha PP, Ouchi T, Kim KT, Nytko E, Kwak JC, Duda RB, Deng CX, Lee SW.

Oncogene. 2003 Jun 12;22(24):3749-58.

PMID:
12802282
9.

Germline TP53 mutations in breast cancer families with multiple primary cancers: is TP53 a modifier of BRCA1?

Martin AM, Kanetsky PA, Amirimani B, Colligon TA, Athanasiadis G, Shih HA, Gerrero MR, Calzone K, Rebbeck TR, Weber BL.

J Med Genet. 2003 Apr;40(4):e34. No abstract available.

10.

The codon 72 polymorphic variants of p53 have markedly different apoptotic potential.

Dumont P, Leu JI, Della Pietra AC 3rd, George DL, Murphy M.

Nat Genet. 2003 Mar;33(3):357-65.

PMID:
12567188
11.

Evidence against involvement of p53 polymorphism in breast cancer predisposition.

Suspitsin EN, Buslov KG, Grigoriev MY, Ishutkina JG, Ulibina JM, Gorodinskaya VM, Pozharisski KM, Berstein LM, Hanson KP, Togo AV, Imyanitov EN.

Int J Cancer. 2003 Jan 20;103(3):431-3. Review. No abstract available.

12.

p53 Genotypes and Haplotypes Associated With Lung Cancer Susceptibility and Ethnicity.

Wu X, Zhao H, Amos CI, Shete S, Makan N, Hong WK, Kadlubar FF, Spitz MR.

J Natl Cancer Inst. 2002 May 1;94(9):681-90.

PMID:
11983757
13.

A link between the p53 germ line polymorphisms and white blood cells apoptosis in lung cancer patients.

Biros E, Kohút A, Biros I, Kalina I, Bogyiová E, Stubna J.

Lung Cancer. 2002 Mar;35(3):231-5.

PMID:
11844595
14.

Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer.

Jonkers J, Meuwissen R, van der Gulden H, Peterse H, van der Valk M, Berns A.

Nat Genet. 2001 Dec;29(4):418-25.

15.

p53 germline polymorphisms are associated with an increased risk for breast cancer in German women.

Wang-Gohrke S, Rebbeck TR, Besenfelder W, Kreienberg R, Runnebaum IB.

Anticancer Res. 1998 May-Jun;18(3B):2095-9.

PMID:
9677474
16.

p53 haplotype determination in breast cancer.

Weston A, Pan CF, Ksieski HB, Wallenstein S, Berkowitz GS, Tartter PI, Bleiweiss IJ, Brower ST, Senie RT, Wolff MS.

Cancer Epidemiol Biomarkers Prev. 1997 Feb;6(2):105-12.

Supplemental Content

Support Center